Family history of non-hematologic cancers among Waldenstrom macroglobulinemia patients: A preliminary study

被引:4
|
作者
Ojha, Rohit P. [1 ]
Hanzis, Christina A. [2 ]
Hunter, Zachary R. [2 ]
Greenland, Sander [3 ,4 ]
Offutt-Powell, Tabatha N. [5 ]
Manning, Robert J. [2 ]
Lewicki, Megan [2 ]
Brodsky, Philip S. [2 ]
Ioakimidis, Leukothea [2 ]
Tripsas, Christina K. [2 ]
Patterson, Christopher J. [2 ]
Sheehy, Patricia [2 ]
Singh, Karan P. [6 ]
Treon, Steven P. [2 ,7 ]
机构
[1] Dana Farber Canc Inst, Div Populat Sci, Boston, MA 02115 USA
[2] Dana Farber Canc Inst, Bing Ctr Waldenstroms Macroglobulinemia, Boston, MA 02115 USA
[3] Univ Calif Los Angeles, Sch Publ Hlth, Dept Epidemiol, Los Angeles, CA 90024 USA
[4] Univ Calif Los Angeles, Coll Letters & Sci, Dept Stat, Los Angeles, CA USA
[5] Univ N Texas, Hlth Sci Ctr, Dept Epidemiol, Sch Publ Hlth, Ft Worth, TX USA
[6] Univ N Texas, Hlth Sci Ctr, Dept Biostat, Sch Publ Hlth, Ft Worth, TX USA
[7] Harvard Univ, Sch Med, Boston, MA USA
关键词
Waldenstrom Macroglobulinemia; Epidemiology; Family history; Risk factor; Breast cancer; Colorectal cancer; Lung cancer; Ovarian cancer; Prostate cancer; MUTATIONS;
D O I
10.1016/j.canep.2011.10.010
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Little is known about the epidemiology and etiology of Waldenstrom macroglobulinemia (WM). Despite several studies of the relation between family history and B-cell disorders and WM, family history of non-hematologic cancers has not been systematically investigated. We thus examined associations of family history of breast, colorectal, lung, ovarian, and prostate cancers with WM. Methods: All probands aged 20-79 years with bone marrow biopsy-confirmed diagnosis of WM between May 1, 1999 and January 1, 2010 at the Bing Center for Waldenstrom Macroglobulinemia were eligible for inclusion in our analysis. We reviewed medical records for eligible probands to determine family history of cancer (defined as a cancer diagnosis for >1 first-degree relative(s) of the proband). Using expected values constructed from the United States National Health Interview Survey, we estimated age- and race-standardized rate ratios (RRs) for family history of breast, colorectal, lung, ovarian, and prostate cancers by WM subtype. Results: Family history of prostate cancer had the largest overall rate ratio (RR = 1.4, 95% confidence limits [CL]: 1.1, 1.7), and among sporadic cases, family history of prostate and breast cancer had the largest rate ratios (prostate: RR = 1.3, 95% CL: 1.1, 1.7; breast: RR = 1.3, 95% CL: 1.2, 1.6). Conclusion: Our study suggests that it may be worthwhile to pursue these associations in a case-control study with uniform selection and data collection for cases and controls, and at least some record-based information on family history. (C) 2011 Elsevier Ltd. All rights reserved.
引用
收藏
页码:294 / 297
页数:4
相关论文
共 50 条
  • [41] Outcome Disparities among Ethntic Subgroups of Waldenstrom's Macroglobulinemia: A Population-Based Study
    Ailawadhi, Sikander
    Kardosh, Adel
    Yang, Dongyun
    Cozen, Wendy
    Patel, Gaurav
    Alamgir, Mohammad A.
    Chanan-Khan, Asher A.
    ONCOLOGY, 2014, 86 (5-6) : 253 - 262
  • [42] Phase I study of bryostatin 1, a protein kinase C modulator, preceding cisplatin in patients with refractory non-hematologic tumors
    Anna C. Pavlick
    Jennifer Wu
    John Roberts
    Mark A. Rosenthal
    Anne Hamilton
    Scott Wadler
    Kathleen Farrell
    Michelle Carr
    David Fry
    Anthony J. Murgo
    Ruth Oratz
    Howard Hochster
    Leonard Liebes
    Franco Muggia
    Cancer Chemotherapy and Pharmacology, 2009, 64
  • [43] Phase I dose escalation study of a polymeric micellar formulation of paclitaxel in patients (pts) with refractory non-hematologic cancer.
    Washart, ML
    Ryan, DP
    Lynch, TJ
    Wang, Z
    Appleman, L
    Shapiro, G
    Clark, JW
    Magrogan, L
    Trapnell, CB
    Eder, JP
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 156S - 156S
  • [44] Multicenter Prospective Phase II Study of Venetoclax in Patients with Previously Treated Waldenstrom Macroglobulinemia
    Castillo, Jorge J.
    Gustine, Joshua
    Meid, Kirsten
    Dubeau, Toni
    Keezer, Andrew
    Allan, John N.
    Furman, Richard R.
    Siddiqi, Tanya
    Advani, Ranjana
    Lam, Jessica
    Hunter, Zachary R.
    Yang, Guang
    Xu, Lian
    Davids, Matthew S.
    Treon, Steven P.
    BLOOD, 2018, 132
  • [45] Phase I study of bryostatin 1, a protein kinase C modulator, preceding cisplatin in patients with refractory non-hematologic tumors
    Pavlick, Anna C.
    Wu, Jennifer
    Roberts, John
    Rosenthal, Mark A.
    Hamilton, Anne
    Wadler, Scott
    Farrell, Kathleen
    Carr, Michelle
    Fry, David
    Murgo, Anthony J.
    Oratz, Ruth
    Hochster, Howard
    Liebes, Leonard
    Muggia, Franco
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2009, 64 (04) : 803 - 810
  • [46] A Phase Ib/II Study of Oprozomib in Patients with Advanced Multiple Myeloma and Waldenstrom Macroglobulinemia
    Ghobrial, Irene M.
    Vij, Ravi
    Siegel, David
    Badros, Ashraf
    Kaufman, Jonathan
    Raje, Noopur
    Jakubowiak, Andrzej
    Savona, Michael R.
    Obreja, Mihaela
    Berdeja, Jesus G.
    CLINICAL CANCER RESEARCH, 2019, 25 (16) : 4907 - 4916
  • [47] Multicenter prospective phase II study of venetoclax in patients with previously treated Waldenstrom macroglobulinemia
    Castillo, Jorge
    Allan, John
    Siddiqi, Tanya
    Advani, Ranjana
    Keezer, Andrew
    Gustine, Joshua
    Meid, Kirsten
    Dubeau, Toni
    Lam, Jessica
    Xu, Lian
    Yang, Guang
    Hunter, Zachary
    Furman, Richard
    Davids, Matthew
    Treon, Steven
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E39 - E40
  • [48] Multicenter phase 2 study of daratumumab monotherapy in patients with previously treated Waldenstrom macroglobulinemia
    Castillo, Jorge J.
    Libby, Edward N.
    Ansell, Stephen M.
    Palomba, M. Lia
    Meid, Kirsten
    Flynn, Catherine A.
    Leventoff, Carly
    Hergott, Christopher B.
    Sewastianik, Tomasz
    Morgan, Elizabeth A.
    Carrasco, Ruben
    Fromm, Jonathan R.
    Yang, Guang
    Hunter, Zachary
    Treon, Steven P.
    BLOOD ADVANCES, 2020, 4 (20) : 5089 - 5092
  • [49] Excellent Outcomes Achieved with Medical Management of Chronic Phase CML Patients with Non-Hematologic TKI Intolerance
    Schoenbeck, Kelly L.
    Tummala, Sirisha
    Olin, Rebecca L.
    Goyal, Neha G.
    Dhruva, Anand
    Damon, Lloyd E.
    Logan, Aaron C.
    Smith, Catherine C.
    Shah, Neil P.
    BLOOD, 2020, 136
  • [50] Pharmacokinetics of PF-00562271, a focal adhesion kinase inhibitor, in patients with advanced non-hematologic malignancies
    Xu, Huiping
    Yin, Donghua
    Duncan, Barbara
    Fingert, Howard
    Sharma, Amarnath
    CANCER RESEARCH, 2008, 68 (09)